ArticleFrontiers in cell and developmental biology2020
Preventing Mortality in COVID-19 Patients: Which Cytokine to Target in a Raging Storm?
Article in Frontiers in cell and developmental biology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 37 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
37 citing papers in PubMed, 68 citations in OpenAlex.
- Multiplex Targeted Proteomic Analysis of Cytokine Ratios for ICU Mortality in Severe COVID-19.Proteomes · 2025Article
- Unraveling the COVID-19 Severity Hubs and Interplays in Inflammatory-Related RNA-Protein Networks.International journal of molecular sciences · 2025Article
- Article
- Article
- Role of IL-27 in COVID-19: A Thin Line between Protection and Disease Promotion.International journal of molecular sciences · 2024Review
- Predictive biomarkers of mortality in patients with severe COVID-19 hospitalized in intensive care unit.Frontiers in immunology · 2024Article
- Reduced IFN-γ levels along with changes in hematologic and immunologic parameters are key to COVID-19 severity in Bangladeshi patients.Experimental hematology · 2023Article
- Blood filtering system for COVID-19 management: novel modality of the cytokine storm therapeutics.Frontiers in immunology · 2023Review
- Profiles of host immune impairment inHeliyon · 2022Review
- Microalgae as an Efficient Vehicle for the Production and Targeted Delivery of Therapeutic Glycoproteins against SARS-CoV-2 Variants.Marine drugs · 2022Review
- Cytokines and microRNAs in SARS-CoV-2: What do we know?Molecular therapy. Nucleic acids · 2022Review
- The role of IL-1 family of cytokines and receptors in pathogenesis of COVID-19.Inflammation research : official journal of the European Histamine Research Society ... [et al.] · 2022Article
- Rationale of using the dual chemokine receptor CCR2/CCR5 inhibitor cenicriviroc for the treatment of COVID-19.PLoS pathogens · 2022Review
- Inflammation and Mortality in COVID-19 Hospitalized Patients With and Without Type 2 Diabetes.The Journal of clinical endocrinology and metabolism · 2022Article
- Bioprospecting of microalgae metabolites against cytokine storm syndrome during COVID-19.Molecular biology reports · 2022Review
- MicroRNAs based regulation of cytokine regulating immune expressed genes and their transcription factors in COVID-19.Meta gene · 2022Article
- Races of small molecule clinical trials for the treatment of COVID-19: An up-to-date comprehensive review.Drug development research · 2022Review
- Phosphate and IL-10 concentration as predictors of long-covid in hemodialysis patients: A Brazilian study.Frontiers in immunology · 2022Article
- COVID-19: Mechanistic Model of the African Paradox Supports the Central Role of the NF-κB Pathway.Viruses · 2021Review
- Weighted Gene Co-Expression Network Analysis Combined with Machine Learning Validation to Identify Key Modules and Hub Genes Associated with SARS-CoV-2 Infection.Journal of clinical medicine · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 4 institutions in 2 countries.
Funding
Abstract
Coronavirus disease 2019 (COVID-19) from severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection has resulted in tremendous morbidity and mortality worldwide. A major underlying cause of COVID-19 mortality is a hyperinflammatory cytokine storm in severe/critically ill patients. Although many clinical trials are testing the efficacy of targeting inflammatory cytokines/chemokines in COVID-19 patients, the critical inflammatory mediator initiating COVID-19 patient death is undefined. Here we suggest that the immunopathological pathway leading to COVID-19 mortality can be divided into three stages with distinct clinical features that can be used to guide therapeutic strategies. Our interpretation of the recently published clinical trials from COVID-19 patients suggests that the clinical efficacy in preventing COVID-19 mortality using IL-1 blockade is subjected to notable caveats, while that for IL-6 blockade is suboptimal. We discuss critical factors in determining appropriate inflammatory cytokine/chemokine targets, timing, and combination of treatments to prevent COVID-19 mortality.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.